Facebook
Twitter
LinkedIn
ForwardRadiation Therapy for Lung Cancer - Best Practices and Current Trends 2024
The treatment approaches for lung cancer are rapidly evolving and include integration of new systemic therapies (e.g., immunotherapy and targeted therapies) into combined modality approaches for non-metastatic disease and ablative radiation therapy approaches for oligometastatic disease. As an example, there is emerging data on immunotherapy combined with chemotherapy as neoadjuvant therapy for surgery in locally advanced non-small cell lung cancer, but no direct head-to-head comparison with chemoradiation plus immunotherapy, which creates a gap in knowledge on how to manage these patients.
This activity reviews recent literature and guidelines for the treatment of lung cancer, and provides insights into tailoring of different combined modality therapy options for patients. Attendees will learn about the clinical outcomes and toxicity risks, and how to coordinate these new, complex multidisciplinary treatment approaches. Furthermore, this session reviews recent insights into toxicity risks for both conventional radiation therapy (especially in the postoperative setting and related to cardiac injury) and stereotactic body radiation therapy (especially for ultracentral tumors), and the implications of radiation therapy toxicity on newer combined modality approaches.
This activity is available from October 10, 2024, through 11:59 p.m. Eastern time on March 31, 2025.
This activity was originally presented and recorded at the 2024 ASTRO Annual Refresher Course.
Target Audience
The activity is designed to meet the interests of practicing radiation oncologists, radiation oncology residents, medical and clinical physicists, radiation therapists, radiation dosimetrists, nurses and all other health professionals involved in the field of radiation oncology.
Learning Objectives
Upon completion of this activity, participants should be able to do the following:
- Discuss the literature supporting novel combined modality therapy approaches that include immunotherapy, chemotherapy, surgery and/or radiation therapy in non-metastatic lung cancer.
- Discuss the pros and cons of different modalities of local therapy (surgery versus radiation) for each stage of lung cancer and appropriate situations to consider dual local therapy.
- Understand risk factors for severe radiation-related toxicity, including cardiac injury and central mediastinal structure injury for SBRT, and methods to mitigate these risks.
Raymond H. Mak, MD is employed by Brigham and Women's Hospital. Dr. Mak receives honoraria from AstraZeneca and honoraria, travel expenses, and grant/research funding as an Advisory Board member and consultant for ViewRay.
The person(s) above served as the developer(s) of this activity. Additionally, the ASTRO Annual Refresher Course Program Committee and the ASTRO Education Committee had control over the content of this activity. A list of all meeting planning committee members and their individual disclosures can be found on the Planning Committee webpage.
All relevant financial relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
Available Credit
- 1.50 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.50 Certificate of AttendanceThis activity was designated for 1.50 AMA PRA Category 1 Credit™.
- 1.50 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.50 self-assessment credits.
Price
Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the discounted member rate.
- Nonmember: $149
- Member: $99
- Member-in-Training: $49
If you are an ASTRO member from a low or lower-middle income country, as identified by the World Bank, you can receive a 50% discount off your corresponding registration for this activity. Please email [email protected] to inquire about the discount.
Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date.
Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.
The activity and its materials will only be available on the ASTRO website until May 31, 2025, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date.
Required Hardware/software
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.